Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EN001
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ENCell’s EN001 Gains FDA Orphan Drug Status for Charcot-Marie-Tooth
Details : EN001 is a mesenchymal stem cell therapy, it targets damaged nerves, promotes the secretion of regenerative factors, and facilitates remyelination. Currently being investigated for CMT.
Product Name : EN001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : EN001
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable